Trial Profile
A study of Natalizumab and Alemtuzumab in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Mar 2018
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 12 Mar 2018 New trial record
- 01 Feb 2018 Results published in the Medicine